Tessier-Lavigne Marc
Former Board of Director at REGN; Director at DNLI; EVP, RESEARCH DRUG DISCOVERY at GENENTECH INC
- Sold, on record
- $92.3M
- Dollars the filings state
- Form 4 sales
- 25
- Latest Nov 23, 2022
- Form 144 notices
- 1
- Proposed sales
- Companies
- 3
- Filed as an executive or holder
Companies
- REGNREGENERON PHARMACEUTICALS, INC.Former Board of Director
- DNLIDenali Therapeutics Inc.Director
- GENENTECH INCEVP, RESEARCH DRUG DISCOVERY
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- DNLI877,509 shares
- REGN100,615 shares
- GENENTECH INC18,750 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale DNLIPlan not statedMar 23, 2022 2022
Sold 20,000 shares at $33.83 ($677k)
Tessier-Lavigne Marc, Director
Sold 1% of holdings ($69.2M position)2M shares left0.3x usual sizeFiling
- 2 Form 4 sale DNLIPlan not statedJul 25, 2022 +124 days
Sold 20,000 shares at $35.61 ($712k)
Tessier-Lavigne Marc, Director
Sold 1% of holdings ($70.2M position)2M shares left0.4x usual sizeFiling
- 3 Form 4 sale DNLIPlan not statedAug 23, 2022 +29 days
Sold 20,000 shares at $31.61 ($632k)
Tessier-Lavigne Marc, Director
Sold 1% of holdings ($61.7M position)1.9M shares left0.4x usual sizeFiling
- 4 Form 4 sale DNLIPlan not statedSep 28, 2022 +36 days
Sold 20,000 shares at $30.82 ($616k)
Tessier-Lavigne Marc, Director
Sold 1% of holdings ($59.5M position)1.9M shares left0.4x usual sizeFiling
- 5 Form 4 sale REGNUnusualOct 3, 2022 +5 days
Sold 10,838 shares at $702.24 ($7.6M)
Tessier-Lavigne Marc, Director
Sold 82.7% of holdings ($9.2M position)2,269 shares left1.1x usual sizeFiling
- 6 Form 4 sale DNLIPlan not statedNov 2, 2022 +30 days
Sold 20,000 shares at $30.27 ($605k)
Tessier-Lavigne Marc, Director
Sold 1% of holdings ($57.8M position)1.9M shares left0.6x usual sizeFiling
- 7 Form 4 sale DNLIPlan not statedNov 23, 2022 +21 days
Sold 20,000 shares at $30.48 ($610k)
Tessier-Lavigne Marc, Director
Sold 1.1% of holdings ($57.6M position)1.9M shares left1x usual sizeFiling
- 8 Form 144 notice REGNNoticeOct 3, 2023 +314 days
Filed to sell 16,362 shares ($13.2M)
Tessier-Lavigne Marc, Former Board of Director
No 10b5-1 plan1.8x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (26)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Oct 3, 2023 | Oct 3, 2023 | REGN | Former Board of Director | Form 144 notice | 16,362 | $13.2M | Notice | SEC | |
| Nov 23, 2022 | Nov 28, 2022 | DNLI | Director | Form 4 sale | 20,000 | $610k | 1.1% | Plan not stated | SEC |
| Nov 2, 2022 | Nov 3, 2022 | DNLI | Director | Form 4 sale | 20,000 | $605k | 1.0% | Plan not stated | SEC |
| Oct 3, 2022 | Oct 3, 2022 | REGN | Director | Form 4 sale | 10,838 | $7.6M | 82.7% | Unusual | SEC |
| Sep 28, 2022 | Sep 30, 2022 | DNLI | Director | Form 4 sale | 20,000 | $616k | 1.0% | Plan not stated | SEC |
| Aug 23, 2022 | Aug 25, 2022 | DNLI | Director | Form 4 sale | 20,000 | $632k | 1.0% | Plan not stated | SEC |
| Jul 25, 2022 | Jul 27, 2022 | DNLI | Director | Form 4 sale | 20,000 | $712k | 1.0% | Plan not stated | SEC |
| Mar 23, 2022 | Mar 25, 2022 | DNLI | Director | Form 4 sale | 20,000 | $677k | 1.0% | Plan not stated | SEC |
| Mar 21, 2022 | Mar 23, 2022 | REGN | Director | Form 4 sale | 7,439 | $5.1M | 76.6% | Unusual | SEC |
| Mar 17, 2022 | Mar 18, 2022 | REGN | Director | Form 4 sale | 12,191 | $8.3M | 84.3% | Unusual | SEC |
| Dec 30, 2021 | Dec 30, 2021 | DNLI | Director | Form 4 sale | 63,131 | $2.8M | 44.5% | Unusual | SEC |
| Dec 9, 2021 | Dec 10, 2021 | REGN | Director | Form 4 sale | 3,784 | $2.5M | 64.6% | Unusual | SEC |
| Sep 13, 2021 | Sep 15, 2021 | REGN | Director | Form 4 sale | 12,750 | $8.2M | 86.0% | Unusual | SEC |
| Jun 7, 2021 | Jun 8, 2021 | DNLI | Director | Form 4 sale | 94,378 | $6.6M | 3.6% | Plan not stated | SEC |
| May 24, 2021 | May 24, 2021 | DNLI | Director | Form 4 sale | 46,763 | $2.8M | 1.8% | Plan not stated | SEC |
| May 3, 2021 | May 5, 2021 | DNLI | Director | Form 4 sale | 3,237 | $195k | 0.1% | Plan not stated | SEC |
| Apr 1, 2021 | Apr 5, 2021 | DNLI | Director | Form 4 sale | 50,000 | $2.8M | 1.9% | Plan not stated | SEC |
| Mar 1, 2021 | Mar 3, 2021 | DNLI | Director | Form 4 sale | 100,000 | $6.6M | 3.6% | Plan not stated | SEC |
| Jun 16, 2020 | Jun 18, 2020 | DNLI | Director | Form 4 sale | 400,000 | $10.4M | 12.7% | Plan not stated | SEC |
| May 6, 2020 | May 8, 2020 | REGN | Director | Form 4 sale | 15,000 | $8.5M | 89.1% | Unusual | SEC |
| Feb 13, 2020 | Feb 14, 2020 | REGN | Director | Form 4 sale | 14,279 | $5.7M | 88.6% | Unusual | SEC |
| Aug 5, 2015 | Aug 5, 2015 | REGN | Director | Form 4 sale | 5,000 | $3M | 80.8% | Unusual | SEC |
| Feb 26, 2015 | Feb 27, 2015 | REGN | Director | Form 4 sale | 3,000 | $1.3M | 71.7% | Unusual | SEC |
| Aug 27, 2014 | Aug 27, 2014 | REGN | Director | Form 4 sale | 3,000 | $1.1M | 71.7% | Unusual | SEC |
| May 6, 2013 | May 8, 2013 | REGN | Director | Form 4 sale | 13,334 | $3.5M | 100.0% | Unusual | SEC |
| Jul 16, 2008 | Jul 18, 2008 | GENENTECH INC | EVP, RESEARCH DRUG DISCOVERY | Form 4 sale | 18,750 | $1.5M | 94.2% | Unusual | SEC |